Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367652 · ClinicalTrials.gov registry record · Phase 1
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
A Phase 1 study of Breast Cancer, sponsored by Roxane Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01367652 is a Phase 1 study of Breast Cancer that has completed, run by Roxane Laboratories. The registered enrollment target is 28 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01367652, a Phase 1 study of Breast Cancer, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Letrozole Tablet under fasted conditions.
Conditions Studied
Interventions
- DRUG Letrozole
Study Locations (1)
North Dakota
- PRACS Institute, Ltd. - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01367652
The ClinicalTrials.gov registry entry for NCT01367652 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Letrozole is the first listed.
NCT01367652 reports 1 study location spanning 1 distinct geographic area - top geographies include North Dakota.
Frequently Asked Questions
What is clinical trial NCT01367652 about?
NCT01367652 is a clinical study titled "Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Letrozole Tablet under fasted conditions.
What is the current status of trial NCT01367652?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2008-03. Estimated completion is 2008-04.
What conditions does trial NCT01367652 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01367652?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT01367652?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01367652 being conducted?
This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.